Piramal Pharma Reports Q1 FY27 Results: Revenue Jumps 17%, EBITDA Margin Expands 72%

Piramal Pharma Reports Q1 FY27 Results: Revenue Jumps 17%, EBITDA Margin Expands 72%​

Mumbai, India | July 29, 2026: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a global pharmaceutical and wellness company, announced its unaudited consolidated financial results for the First Quarter (Q1) of Fiscal Year 2027, which ended on June 30, 2026. The company reported healthy revenue growth across all three businesses, accompanied by a significant expansion in EBITDA margin.

Consolidated Financial Highlights​

The Q1 FY27 performance showed strong top-line growth for the company. Revenue from Operations reached ₹2,270 Crores, marking a 17% increase compared to the same quarter last year (₹1,934 Crores). The Earnings Before Interest and Taxes (EBITDA) saw a substantial surge of 72%, rising to ₹285 Crores. EBITDA Margin improved to 12.5%, up from 8.5% in Q1 FY26.

The Net Profit after Taxable Income for the quarter was reported as (₹69) Crores, which is a 32% improvement compared to the prior year's figure of (₹102) Crores.

A summary of the consolidated financial highlights across both quarters is provided below:

Segment Performance and Operational Excellence​

Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that the company started FY27 strongly, with all three business units delivering mid-to-high teens revenue growth and meaningful EBITDA margin expansion.

Contract Development and Manufacturing Organization (CDMO):
The CDMO segment achieved 19% year-on-year revenue growth, driven by broad-based activity across India and overseas sites. The company strengthened its commercial capabilities through an expanded team and improved customer engagement. Operational excellence, higher utilization, and pricing discipline were key factors in driving the EBITDA margin expansion despite inflationary pressures. In terms of capability advancements, Piramal Pharma inaugurated the commercial-scale payload-linker suite at Riverview, US, while the sterile injectable capacity expansion at Lexington, US remains on track. The Sellersville facility also received an Establishment Inspection Report from the US FDA, and the business maintained its Zero OAI status.

Complex Hospital Generics (CHG):
The CHG segment saw 17% revenue growth, maintaining leadership in key therapies. In inhalation anesthesia, Piramal Pharma retained a 48% value share for Sevoflurane in the US market and showed encouraging traction across select ex-US markets. The company also maintained its number one position in the US intrathecal Baclofen market. Supplies of Kenalog® are expected to start from Q2 FY27.

Piramal Consumer Healthcare (PCH):
The PCH business delivered 15% growth, driven by strategic initiatives across its portfolio. Power Brands grew by 23% year-on-year and contributed 53% of the segment's sales. E-commerce grew by 40% year-on-year, accounting for 28% of PCH sales. The business focused on profitable growth through premiumization, judicious pricing, and cost optimization initiatives to mitigate raw material inflation.

Strategic Developments and Future Outlook​

Piramal Pharma Limited is committed to sustained revenue growth and EBITDA expansion throughout FY27. Key strategic updates include:

• CDMO: Continued focus on building the ADC platform; dedicated payload-linker supply is being generated through collaboration with Ajinomoto Bio-Pharma Services.
• CHG: The company continues investing in 505(b)(2) products and differentiated generics to strengthen long-term growth, while preparing for Kenalog® supplies starting in Q2 FY27.
• PCH: The brand portfolio underwent premiumization, complemented by the launch of i-choose, a new master brand consolidating the women's intimate care range.

The company will be hosting an investor conference call on July 30, 2026, to discuss the Q1 FY2027 results further.

PPLPHARMA Stock Price Movement​

Piramal Pharma Limited shares gained 0.81% today, closing at ₹195.68 after settling above its previous close to trade in the healthcare sector. The stock traded 11.85 million shares worth of PPLPHARMA during the day.